Editas Medicine Inc (NASDAQ: EDIT) kicked off on Friday, down -11.24% from the previous trading day, before settling in for the closing price of $2.49. Over the past 52 weeks, EDIT has traded in a range of $0.91-$4.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -1.48% over the past five years. While this was happening, its average annual earnings per share was recorded 34.40%. With a float of $82.96 million, this company’s outstanding shares have now reached $83.71 million.
Let’s look at the performance matrix of the company that is accounted for 246 employees. In terms of profitability, gross margin is 87.72%, operating margin of -726.43%, and the pretax margin is -701.06%.
Editas Medicine Inc (EDIT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.91%, while institutional ownership is 53.87%. The most recent insider transaction that took place on Aug 07 ’25, was worth 1,752. In this transaction SVP, Chief Financial Officer of this company sold 679 shares at a rate of $2.58, taking the stock ownership to the 16,827 shares. Before that another transaction happened on Jul 31 ’25, when Company’s EVP, CHIEF SCIENTIFIC OFFICER sold 5,121 for $2.49, making the entire transaction worth $12,757. This insider now owns 64,398 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.82 earnings per share (EPS), lower than consensus estimate (set at -0.71) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.74% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 1.45 million, a negative change from its year-to-date volume of 2.96 million. As of the previous 9 days, the stock’s Stochastic %D was 11.16%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 48.69%, which indicates a significant increase from 0.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.24 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.45, while its 200-day Moving Average is $1.92. Nevertheless, the first resistance level for the watch stands at $2.42 in the near term. At $2.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.74. If the price goes on to break the first support level at $2.10, it is likely to go to the next support level at $1.99. Assuming the price breaks the second support level, the third support level stands at $1.78.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
The company with the Market Capitalisation of 185.01 million has total of 83,713K Shares Outstanding. Its annual sales at the moment are 32,310 K in contrast with the sum of -237,090 K annual income. Company’s last quarter sales were recorded 4,660 K and last quarter income was -76,090 K.
